Skip to main content

Managing Pharmaceuticals In International Health

Download Managing Pharmaceuticals In International Health Full eBooks in PDF, EPUB, and kindle. Managing Pharmaceuticals In International Health is one my favorite book and give us some inspiration, very enjoy to read. you could read this book anywhere anytime directly from your device. This site is like a library, Use search box in the widget to get ebook that you want.

Managing Pharmaceuticals in International Health

Managing Pharmaceuticals in International Health Book
Author : Stuart Anderson,Reinhard Huss,Robert Summers,Karin Wiedenmayer
Publisher : Birkhäuser
Release : 2004-06-25
ISBN : 9783764366018
File Size : 43,6 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

-Gives a new perspective on the politics of drug supply -Will interest those involved with the management of medicines at any level -Indispensable for students of public health

MDS 3

MDS 3 Book
Author : Management Sciences for Health (Firm)
Publisher : Unknown
Release : 2012-12-31
ISBN : 9781565495876
File Size : 23,9 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

Managing Drug Supply (MDS) is the leading reference on how to manage essential medicines in developing countries. MDS was originally published in 1982; it was revised in 1997 with over 10,000 copies distributed in over 60 countries worldwide. The third edition, MDS-3: Managing Access to Medicines and Health Technologies reflects the dramatic changes in politics and public health priorities, advances in science and medicine, greater focus on health care systems, increased donor funding, and the advent of information technology that have profoundly affected access to essential medicines over the past 14 years. Nearly 100 experts from a wide range of disciplines and virtually every corner of the world have contributed to this third edition. In addition to many new country studies, references, and extensive revisions, MDS-3 offers new chapters on areas such as pharmaceutical benefits in insurance programs, pricing, intellectual property, drug seller initiatives, and traditional and complementary medicine. The revisions and new chapters echo the wide variety of issues that are important to health practitioners and policy makers today. MDS-3 will be a valuable tool in the effort to ensure universal access to quality medicines and health technologies and their appropriate use.

Managing Pharmaceuticals in International Health

Managing Pharmaceuticals in International Health Book
Author : Stuart Anderson,Reinhard Huss,Rob Summers,Karin Wiedenmayer
Publisher : Birkhäuser
Release : 2012-12-06
ISBN : 303487913X
File Size : 25,8 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

-Gives a new perspective on the politics of drug supply -Will interest those involved with the management of medicines at any level -Indispensable for students of public health

Equitable Access to High Cost Pharmaceuticals

Equitable Access to High Cost Pharmaceuticals Book
Author : Zaheer-Ud-Din Babar
Publisher : Academic Press
Release : 2018-02-27
ISBN : 0128119624
File Size : 54,5 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines. Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs Incorporates existing guidelines and recommendations by international organizations Compares and contrasts how different countries fund and police high-cost drug access Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing Reviews novel pharmaceuticals of current research interest

Managing Drug Supply

Managing Drug Supply Book
Author : Management Sciences for Health (Firm)
Publisher : Unknown
Release : 1997
ISBN : 0987650XXX
File Size : 44,7 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

This edition of Managing Drug Supply provides a complete overview, as well as step-by-step approaches, on how to manage pharmaceutical systems effectively.

Countering the Problem of Falsified and Substandard Drugs

Countering the Problem of Falsified and Substandard Drugs Book
Author : Institute of Medicine,Board on Global Health,Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products
Publisher : National Academies Press
Release : 2013-06-20
ISBN : 0309269393
File Size : 27,5 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.

The Selection and Use of Essential Medicines

The Selection and Use of Essential Medicines Book
Author : WHO Expert Committee on the Selection and Use of Essential Medicines,World Health Organization
Publisher : Diamond Pocket Books (P) Ltd.
Release : 2004
ISBN : 9789241209205
File Size : 48,8 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model List of Essential Medicines. The first part contains a progress report on the new procedures for updating the Model List and the development of the WHO Essential Medicines Library. It continues with a section on changes made in revising the Model List followed by a review of some sections such as hypertensive medicines and fast track procedures for deleting items. Annexes include the 13th version of the Model List and items on the list sorted according to their 5-level Anatomical Therapeutic Chemical classification codes.

Pain Management and the Opioid Epidemic

Pain Management and the Opioid Epidemic Book
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse
Publisher : National Academies Press
Release : 2017-09-28
ISBN : 0309459575
File Size : 32,8 Mb
Language : En, Es, Fr and De

DOWNLOAD

Book Summary :

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.